Overview

Cytox Group Limited provides non-invasive, risk assessment and patient stratification tools for Alzheimer's disease and dementia. Cytox’s mission is to transform how new treatments are developed, people are screened, and how patients are managed within the Alzheimer’s disease care pathway..

Alzheimer’s disease today affects over 46 million people globally, projected to reach 75 million in 2030 and over 131 million people by 2050 with an economic impact estimated to exceed $1tn per year in the next decade [World Alzheimer’s Report 2015].

Cytox has two products: genoSCORE™ and genoTOR™ that use blood and saliva, so are non-invasive, and can be used anywhere in the world, on a mass scale, without excessive costs associated with current diagnostic approaches requiring highly specialised PET imaging facilities.

These products enable developers of Alzheimer’s drugs to identify patients most at risk of developing the disease, thus providing options to improve clinical trial enrichment strategies to help optimise patient recruitment needs for various clinical study designs.

genoSCORE™ and genoTOR™ are available on a fee for service basis, through a licensing agreement, or as part of a strategic partnership to develop enabling technologies for use with future marketed drugs.

Cytox is currently preparing genoSCORE™ and genoTOR™ for US and EU regulatory approval. If approved, any newly approved drug will have the option to use genoSCORE™ and genoTOR™ as companion diagnostic tools to identify patients most likely to respond to treatment.

 

 

 

 Cytox has received funding from The European Union's Horizon 2020 research and innovation programme under agreement no. 854998

 

Management Team

Dr Richard Pither, CEO

Richard Pither has been involved in the development of diagnostic and therapeutic pharmaceutical products for more than 20 years. He has held senior R&D and leadership positions in global pharmaceutical companies including GE Healthcare (Medical Diagnostics), UCB-Celltech, Lorantis and Amersham plc. During this time, he was involved in the development of a novel 18F-PET radiopharmaceutical for imaging amyloid deposition in the brains of Alzheimer’s disease patients.

Dr Alex Gibson, Business Development Officer

Alex has over 20 years’ experience working in diagnostics with a substantial track record of delivering value to the business through technology collaboration through partnering. He began in diagnostics R&D and has worked across all disease areas but more specifically in later years within neurodegeneration. As Head of Research Alliances for GE Healthcare he led many initiatives to work across the diagnostic/ therapeutic interface including working with big pharma in the utilisation of PET imaging in Alzheimer’s disease trials.

Dr Paula Daunt, Project and Portfolio Manager

Paula has a wide experience in project management for drug discovery and clinical trials. With a PhD in Theoretical Chemistry, she began as a computational chemist for Zeneca Pharmaceuticals; later joining AstraZeneca as a project manager leading cross functional thematic projects to support and develop novel processes within early drug discovery.  She led up to 4 simultaneous global product teams through early drug discovery to Phase III clinical trials. In 2017 Paula joined Cytox Ltd where she is now responsible for the biomarker project management for Alzheimer’s disease assessment.

Dr Olusegun Oshota, Head of Bioinformatics and Genetics

With extensive experience in bioinformatics and genetics, Olu has a MSc in Molecular Pharmacology and Biotechnology as well as a PhD in Systems Biology. He worked as a bioinformatician for more than 15 years at Montana State University, the University of Manchester and the University of Cambridge. He then worked as data science fellow for S2DS and as a bioinformatician at Discuva. He joined Cytox in 2017.

Tony Hill, Chief Commercial Officer

Tony Hill has been involved in the diagnostics and molecular life sciences industry for 30 years, with especial experience in restructuring and growing domestic and international markets. He has held senior roles in sales and marketing in international diagnostics and molecular life science companies including TwistDx Ltd (part of Abbott Diagnostics), Diasorin Molecular, Innogenetics and Sigma-Aldrich.

Matt Moore, US Sales Manager

Matt Moore has worked within the diagnostics industry for 20 years.  He has experience within the molecular and immunoassay markets with special focuses in infectious disease, oncology, and neurodegenerative disorders; specifically, Alzheimer’s Disease.  He has held management level positions focused on marketing, market development, and sales in the United States.  For the last 10 years, Matt has focused on growing sales for Alzheimer’s Disease related diagnostics and sample collection devices within the academic, service lab, and pharmaceutical industries. 

Board of Directors

Dr Richard Pither, CEO

Richard Pither has been involved in the development of diagnostic and therapeutic pharmaceutical products for more than 20 years. He has held senior R&D and leadership positions in global pharmaceutical companies including GE Healthcare (Medical Diagnostics), UCB-Celltech, Lorantis and Amersham plc. During this time, he was involved in the development of a novel 18F-PET radiopharmaceutical for imaging amyloid deposition in the brains of Alzheimer’s disease patients.

Dr David Whitcombe, Non-executive Director

David is a Venture Partner with Catapult Ventures, having worked alongside Catapult and its portfolio companies for a number of years informally. He has a wealth of experience in diagnostics and molecular biology and understands what it takes to grow a successful life science business. David co-founded DxS Diagnostics in 2000 to expand upon technology he developed at AstraZeneca and sold the company in 2009 to Qiagen for in excess of £100m.

Scientific Advisors and Partners

Professor John Hardy

Professor John Hardy is a geneticist and molecular biologist whose research interests focus on neurological disease. He was Head of the Neurogenetics Section, National Institute of Ageing, Bethesda, USA and in 2007 took up the Chair of Molecular Biology of Neurological Disease at the UCL Institute of Neurology, London, UK. With over 23,000 citations, Professor Hardy is the most cited Alzheimer’s disease researcher in the UK (5th internationally).


Professor Julie Williams C.B.E.

Professor Williams is a senior figure in the field of Alzheimer’s disease genetics research. She is Associate Director of UK Dementia Research Institute at Cardiff, a former Chief Scientific Advisor to the Welsh Government and Alzheimer's Research UK, and she is currently one of the four leaders of the International Genomics of Alzheimer’s Project (IGAP) genetics consortium. This incorporates over 400 scientists from Europe and the USA and has access to more than 90,000 AD cases and controls.

She has identified at least 25 risk loci for Alzheimer’s disease implicating the roles played by immunity, endocytosis and cholesterol processing in disease development.


Professor Valentina Escott-Price

Professor Escott-Price is a genetic statistical expert in Alzheimer’s disease genomic analyses studies, Dementia Research Institute (DRI) at Cardiff, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Wales, UK.


Dr Zsuzsanna Nagy

Cytox’s scientific founder, Dr Nagy, is well known for her groundbreaking work on the involvement of the cell cycle in neurodegenerative diseases which started a new chapter in the history of neurodegeneration research. For over 20 years she has been working on the pathogenic mechanisms of Alzheimer’s disease, novel biomarker development and early stage drug discovery for disease-modifying drugs. In 2004 she moved to Birmingham University Medical School, UK, where she now holds the position of Senior Lecturer and Lead of the Neurodegeneration and Repair team in the Department of Neuropharmacology and Neurobiology.


Professor Harald Hampel

Professor Hampel is a word-leading researcher with vast expertise and reputation in neurology, psychiatry and cutting-edge neuroscience research. With 20 years of experience, he has successfully developed international research programmes dedicated to Alzheimer’s diagnosis and therapeutic algorithms. In 2013 he was awarded the AXA Chair of Alzheimer’s disease, University Salpêtrière Hospital in Paris, University Pierre & Marie Curie (UPMC), Paris, France.


Professor Bruno Dubois

Professor Dubois is principal or co-investigator of a number of research and Government programmes focusing on AD, and dementia in Parkinson’s disease and has published more than 550 peer-reviewed articles in this area. He is Professor of Neurology at the Neurological Institute of the Salpêtrière University Hospital at Paris, UPMC, Paris France, as well as Director of the Behavioural Neurology Department and of the Dementia Research Center at the hospital. 


Associate Professor Simon Laws

Associate Professor Laws’ research primarily focuses on understanding the genetic and epigenetic architecture of Alzheimer’s Disease and related phenotypes.  He is an Associate Professor in the School of Medical and Health Sciences, Edith Cowan University, Perth, Australia where he leads the Collaborative Genomics Group. Simon also currently leads the genetics stream in AIBL (The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing) and from 2011 till the end of 2017 was the Deputy CSO of the Cooperative Research Centre (CRC) for Mental Health.


Investment Partners